{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:48:20Z","timestamp":1777132100452,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013280","name":"Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","award":["20214103"],"award-info":[{"award-number":["20214103"]}],"id":[{"id":"10.13039\/501100013280","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.intimp.2026.116645","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:12:27Z","timestamp":1775898747000},"page":"116645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dose-dependent bidirectional effects of gemcitabine in 4\u00a0T1 breast tumors are associated with angiogenesis and PMN-MDSC\u2013linked immunosuppression"],"prefix":"10.1016","volume":"179","author":[{"given":"Yanshen","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaowei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengpeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116645_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21037\/tbcr-22-12","article-title":"Narrative review of current status and recommendations in treatment for advanced triple-negative breast cancer","volume":"3","author":"Zhou","year":"2022","journal-title":"Transl Breast Cancer Res."},{"issue":"14","key":"10.1016\/j.intimp.2026.116645_bb0010","article-title":"Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies","volume":"28","author":"Xiong","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.116645_bb0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/BCTT.S516542","article-title":"Diagnosis, prognosis, and treatment of triple-negative breast cancer: a review","volume":"17","author":"Jie","year":"2025","journal-title":"BCTT"},{"issue":"12","key":"10.1016\/j.intimp.2026.116645_bb0020","article-title":"Vascular microenvironment, tumor immunity and immunotherapy","volume":"20","author":"Lamplugh","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116645_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081822","article-title":"How chemotherapy affects the tumor immune microenvironment: a narrative review","volume":"10","author":"Merlano","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.intimp.2026.116645_bb0030","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00280-011-1563-6","article-title":"Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model","volume":"68","author":"Wu","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116645_bb0035","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/sj.bjc.6604352","article-title":"Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib","volume":"98","author":"Bocci","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116645_bb0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"Wang","year":"2021","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.intimp.2026.116645_bb0045","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S1470-2045(25)00545-5","article-title":"Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial","volume":"26","author":"Yuan","year":"2025","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116645_bb0050","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2026.116645_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120826","article-title":"Promotion of tumor progression induced by continuous low-dose administration of antineoplastic agent gemcitabine or gemcitabine combined with cisplatin","volume":"306","author":"Chen","year":"2022","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.intimp.2026.116645_bb0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/ijo.2023.5601","article-title":"Dual-directional effect of vinorelbine combined with cisplatin or fluorouracil on tumor growth and metastasis in metronomic chemotherapy in breast cancer","volume":"64","author":"Liu","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116645_bb0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/fcp.12939","article-title":"Dose-dependent bidirectional pharmacological effects of vinorelbine-based metronomic combination chemotherapy on tumor growth and metastasis and mechanisms in melanoma mouse model","volume":"38","author":"Liu","year":"2024","journal-title":"Fundamemntal Clinical Pharma."},{"issue":"8","key":"10.1016\/j.intimp.2026.116645_bb0070","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"7649","key":"10.1016\/j.intimp.2026.116645_bb0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2026.116645_bb0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression","volume":"39","author":"Motz","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.116645_bb0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.canlet.2017.02.005","article-title":"The potential clinical promise of \u2018multimodality\u2019 metronomic chemotherapy revealed by preclinical studies of metastatic disease","volume":"400","author":"Kerbel","year":"2017","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.intimp.2026.116645_bb0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-013-2125-x","article-title":"Metronomic chemotherapy for cancer treatment: a decade of clinical studies","volume":"72","author":"Romiti","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116645_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216997","article-title":"The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma","volume":"595","author":"Ito","year":"2024","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.intimp.2026.116645_bb0100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"7\u20138","key":"10.1016\/j.intimp.2026.116645_bb0105","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.intimp.2009.03.015","article-title":"Gemcitabine directly inhibits myeloid derived suppressor cells in BALB\/c mice bearing 4T1 mammary carcinoma and augments expansion of t cells from tumor-bearing mice","volume":"9","author":"Le","year":"2009","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116645_bb0110","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccr.2013.02.013","article-title":"Macrophage regulation of tumor responses to anticancer therapies","volume":"23","author":"De Palma","year":"2013","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.intimp.2026.116645_bb0115","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","article-title":"Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance","volume":"358","author":"Kareva","year":"2015","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.intimp.2026.116645_bb0120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3892\/ijo.2015.3059","article-title":"Metronomic vinorelbine: anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by akt inhibition","volume":"47","author":"Mavroeidis","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116645_bb0125","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2026.116645_bb0130","first-page":"307","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic","volume":"307","author":"Jain","year":"2005","journal-title":"Therapy"},{"key":"10.1016\/j.intimp.2026.116645_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114201","article-title":"Precision cancer medicine platform trials: concepts and design of AcS\u00e9-ESMART","volume":"208","author":"Geoerger","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.116645_bb0140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/PPO.0000000000000134","article-title":"A decade of experience in developing preclinical models of advanced- or early-stage spontaneous metastasis to study antiangiogenic drugs, metronomic chemotherapy, and the tumor microenvironment","volume":"21","author":"Kerbel","year":"2015","journal-title":"Cancer J."},{"key":"10.1016\/j.intimp.2026.116645_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216382","article-title":"Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: special focus on resistance mechanisms and metronomic therapies","volume":"573","author":"Natu","year":"2023","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.intimp.2026.116645_bb0150","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.neo.2014.05.011","article-title":"Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy","volume":"16","author":"Hasnis","year":"2014","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.intimp.2026.116645_bb0155","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory t cells and restores t and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.intimp.2026.116645_bb0160","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ccr.2008.08.001","article-title":"Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents","volume":"14","author":"Shaked","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.116645_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1275375","article-title":"Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer","volume":"14","author":"Bazargan","year":"2023","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2026.116645_bb0170","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3390\/cells13161317","article-title":"Tissue- and temporal-dependent dynamics of myeloablation in response to gemcitabine chemotherapy","volume":"13","author":"Kitelinger","year":"2024","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.intimp.2026.116645_bb0175","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1159\/000110580","article-title":"Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients \u2013 results of a phase II study","volume":"30","author":"Steinbild","year":"2007","journal-title":"Oncol. Res. Treat."},{"issue":"6","key":"10.1016\/j.intimp.2026.116645_bb0180","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1424927112","article-title":"Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils","volume":"112","author":"Casbon","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"50","key":"10.1016\/j.intimp.2026.116645_bb0185","doi-asserted-by":"crossref","first-page":"21248","DOI":"10.1073\/pnas.1015855107","article-title":"Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes","volume":"107","author":"Kowanetz","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.intimp.2026.116645_bb0190","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1172\/JCI74056","article-title":"ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R\u2013mediated apoptosis","volume":"124","author":"Condamine","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.intimp.2026.116645_bb0195","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116645_bb0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ccr.2010.11.009","article-title":"HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF","volume":"19","author":"Rolny","year":"2011","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.intimp.2026.116645_bb0205","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2008.09.004","article-title":"Tumor-targeted interferon-\u03b1 delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis","volume":"14","author":"De Palma","year":"2008","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.intimp.2026.116645_bb0210","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.116645_bb0215","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41419-019-1723-x","article-title":"Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL-1\u03b2 secretion in 5-fluorouracil-treated MDSC: implication in cancer treatment","volume":"10","author":"Dumont","year":"2019","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.intimp.2026.116645_bb0220","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1007\/s00432-021-03657-9","article-title":"Angiogenesis and chemotherapy resistance: optimizing chemotherapy scheduling using mathematical modeling","volume":"147","author":"Bodzioch","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116645_bb0225","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2016.11.007","article-title":"Metronomic chemotherapy and nanocarrier platforms","volume":"400","author":"Abu Lila","year":"2017","journal-title":"Cancer Lett."},{"issue":"237","key":"10.1016\/j.intimp.2026.116645_bb0230","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.intimp.2026.116645_bb0235","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.intimp.2026.116645_bb0240","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-related inflammation and treatment effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600490X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600490X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:17:20Z","timestamp":1777130240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692600490X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":48,"alternative-id":["S156757692600490X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116645","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-dependent bidirectional effects of gemcitabine in 4\u00a0T1 breast tumors are associated with angiogenesis and PMN-MDSC\u2013linked immunosuppression","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116645"}}